Top Markets
Coin of the day
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Pozycja w akcjach #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Cena akcji
$1.73
Ostatnia synchronizacja: 2025-06-17
Kapitalizacja rynkowa
$2.55M
Zmiana (1 dzień)
-0.29%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)

Kategoria

Wskaźnik P/S dla Eiger BioPharmaceuticals, Inc. (EIGR)
Wskaźnik P/S na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji Eiger BioPharmaceuticals, Inc., obecny wskaźnik P/S (TTM) wynosi 0. Na koniec 2026 wynosił 0.
Historia wskaźnika P/S dla Eiger BioPharmaceuticals, Inc. od 2026 do 2026
Wskaźnik P/S na koniec każdego roku
Rok Wskaźnik P/S Zmień
Za mało danych dla podanych dat.
Wskaźnik P/S dla podobnych firm lub konkurentów
Firma Wskaźnik P/S Różnica wskaźnika P/S Kraj
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE